United States General Anesthesia Drugs Market 2015 - Molecule, Route of Administration, Supply Chain & Competitive Analysis to 2020

Aug 05, 2015, 12:10 ET from Research and Markets

DUBLIN, Aug. 05, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/vr6xj9/u_s_general) has announced the addition of the "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020" report to their offering.

The U.S. general anesthesia drugs market is poised to reach USD 2.0 Billion by 2020 from USD 1.6 Billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are key factors driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

The U.S. general anesthesia drugs market is segmented on the basis of molecule and route of administration. On the basis of molecule, the market is segmented into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of the market.

Key players operating in the U.S. general anesthesia drugs market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Market Overview

4 Distribution Structure

5 Product Analysis

6 U.S. General Anesthesia Drugs Market: Key Information

7 Strategic Recommendations for Entering the U.S. General Anesthesia Drugs Market

8 Company Profiles

- Abbott Laboratories
- Astrazeneca PLC
- Baxter International Inc.
- Eisai Co., Ltd.
- Fresenius Se & Co. Kgaa
- Hikma Pharmaceuticals PLC
- Hospira, Inc.
- Mylan N.V.
- Par Pharmaceutical Companies, Inc.

For more information visit http://www.researchandmarkets.com/research/vr6xj9/u_s_general

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets